Get the Stockscreener App
39.05
1.43%
0.55
After Hours:
39.00
-0.05
-0.13%
Omnicell Inc stock is traded at $39.05, with a volume of 1.35M.
It is up +1.43% in the last 24 hours and down -9.65% over the past month.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
See More
Previous Close:
$38.50
Open:
$38.97
24h Volume:
1.35M
Relative Volume:
2.34
Market Cap:
$1.78B
Revenue:
$1.23B
Net Income/Loss:
$20.43M
P/E Ratio:
88.53
EPS:
0.4411
Net Cash Flow:
$95.39M
1W Performance:
+3.25%
1M Performance:
-9.65%
6M Performance:
-15.57%
1Y Performance:
+38.13%
1-Day Range:
$37.63
$39.41
1-Week Range:
$37.44
$40.67
52-Week Range:
$26.84
$55.00
Omnicell Inc Stock (OMCL) Company Profile
Name
Omnicell Inc
Sector
Industry
Phone
(877) 415-9990
Address
4220 NORTH FREEWAY, FORT WORTH
Compare OMCL vs VEEV, BTSG, TEM, HQY, HNGE
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMCL
Omnicell Inc
|
39.05 | 1.75B | 1.23B | 20.43M | 95.39M | 0.4411 |
VEEV
Veeva Systems Inc
|
153.30 | 25.15B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
66.25 | 12.64B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
50.84 | 8.76B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
85.21 | 7.22B | 1.34B | 230.70M | 440.96M | 2.6695 |
HNGE
Hinge Health Inc
|
69.42 | 5.19B | 646.34M | -512.40M | 202.76M | -6.6871 |
Omnicell Inc Stock (OMCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-26 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-08-26 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| May-14-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-03-24 | Initiated | Barclays | Underweight |
| Nov-03-23 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-03-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-11-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Sep-26-23 | Reiterated | Wells Fargo | Underweight |
| Aug-02-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-23 | Downgrade | Wells Fargo | Overweight → Underweight |
| Feb-27-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-03-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-09-22 | Initiated | BofA Securities | Buy |
| Jul-15-22 | Initiated | SVB Leerink | Mkt Perform |
| Dec-06-21 | Resumed | Wells Fargo | Overweight |
| Jun-09-21 | Initiated | JP Morgan | Neutral |
| May-24-21 | Initiated | BTIG Research | Buy |
| Feb-02-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-20 | Initiated | Berenberg | Buy |
| Dec-03-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-20 | Initiated | Stephens | Overweight |
| Feb-07-20 | Reiterated | Dougherty & Company | Buy |
| Nov-21-19 | Reiterated | Dougherty & Company | Buy |
| Jul-26-19 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-07-19 | Reiterated | Dougherty & Company | Buy |
| Jun-29-18 | Resumed | The Benchmark Company | Buy |
| Sep-05-17 | Reiterated | The Benchmark Company | Buy |
| Jul-28-17 | Reiterated | Dougherty & Company | Buy |
| Apr-21-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-19-17 | Initiated | Dougherty & Company | Buy |
| Dec-06-16 | Reiterated | The Benchmark Company | Buy |
| Jul-07-16 | Reiterated | FBR Capital | Outperform |
| Mar-21-16 | Reiterated | Topeka Capital Markets | Buy |
| Jan-07-16 | Initiated | The Benchmark Company | Buy |
| Nov-16-15 | Reiterated | Topeka Capital Markets | Buy |
| Oct-30-15 | Reiterated | FBR Capital | Outperform |
| Sep-28-15 | Upgrade | Sidoti | Neutral → Buy |
| Jul-31-15 | Reiterated | Topeka Capital Markets | Buy |
View All
Omnicell Inc Stock (OMCL) Latest News
Omnicell StockThursday chart update with 200-day line in view - AD HOC NEWS
Omnicell Inc (OMCL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Omnicell Inc (OMCL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Omnicell Inc (OMCL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Liquidity Mapping Around (OMCL) Price Events - Stock Traders Daily
Omnicell Inc (OMCL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Omnicell Inc (OMCL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Omnicell Inc (OMCL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Omnicell Inc (OMCL) Institutional Confidence - TradingKey
Omnicell Inc (OMCL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Omnicell Inc (OMCL) Valuation: PE, PB & Fair Value Analysis - TradingKey
What Omnicell (OMCL)'s New Specialty Pharmacy Leader Means For Shareholders - simplywall.st
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Oric Pharmaceuticals (ORIC) and Pfizer (PFE) - The Globe and Mail
Omnicell (NASDAQ:OMCL) Trading Down 4.9%Time to Sell? - MarketBeat
Omnicell (OMCL) is a top-ranked value stock: Should you buy? - MSN
Transcript : Omnicell, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 03 - marketscreener.com
Omnicell: Why I’m Long Into Q2 Earnings Despite The Bookings Wobble (NASDAQ:OMCL) - Seeking Alpha
Earnings Preview: Omnicell to Report Financial Results Pre-market on April 28 - Moomoo
Omnicell appoints Dan Mandoli to lead specialty pharmacy unit - Investing.com UK
Omnicell, Inc. Announces Appointment of Dan Mandoli to Senior Vice President and General Manager, Specialty Pharmacy Services - marketscreener.com
Omnicell appoints Dan Mandoli to lead specialty pharmacy unit By Investing.com - Investing.com South Africa
Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business - 巴士的報
Intech Investment Management LLC Sells 30,447 Shares of Omnicell, Inc. $OMCL - MarketBeat
Omnicell (OMCL) may find a bottom soon, here's why you should buy the stock now - MSN
Omnicell Shareholders Back Governance Amendment And Long Term Growth Focus - Yahoo Finance
Should Omnicell’s (OMCL) Governance Moves and Conference Spotlight Recast Its Recurring Revenue Narrative? - Sahm
OMCL Technical Analysis & Stock Price Forecast - Intellectia AI
Why (OMCL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Q1 2026 Earnings Analysis: Healthcare Tech for Providers Sector PerformanceNews and Statistics - IndexBox
Wall Street Analysts Predict a 40.57% Upside in Omnicell (OMCL): Here's What You Should Know - Yahoo Finance
Omnicell (OMCL) is a top-ranked momentum stock: Should you buy? - MSN
Omnicell (OMCL) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
A Look at Omnicell Inc (OMCL) After 4.1% Gain -- GF Value $38.65 vs Price $43.62 - GuruFocus
Is Omnicell Stock a Smart Addition to Your Portfolio Now? - Zacks Investment Research
Omnicell (OMCL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - sharewise.com
Omnicell (OMCL) director receives 4,785-share stock grant - Stock Titan
Omnicell (OMCL) director granted 4,845 restricted shares as board pay - Stock Titan
Omnicell (OMCL) director awarded 4,603 restricted shares as board compensation - Stock Titan
Omnicell (OMCL) director Mark Parrish receives 4,845-share board compensation grant - Stock Titan
Omnicell (NASDAQ: OMCL) director receives 4,603-share restricted stock award - Stock Titan
[Form 4] OMNICELL, INC. Insider Trading Activity - Stock Titan
Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - BioSpace
Omnicell (OMCL) director Joanne Bauer receives 5,027-share equity grant for board service - Stock Titan
Omnicell Inc stock (US6821321088): Shares little changed as investors look beyond last earnings upda - AD HOC NEWS
Omnicell Inc stock (US6821321088): OMCL gains on Nasdaq as short interest edges above 6 percent - AD HOC NEWS
A Look At Omnicell (OMCL) Valuation After Upbeat Q1 Results And Raised Earnings Guidance - simplywall.st
Omnicell (OMCL) up 0.1% since last earnings report: Can it continue? - MSN
Surging earnings estimates signal upside for Omnicell (OMCL) stock - MSN
Omnicell lifts 2026 non-GAAP EPS outlook to $1.80-$2.00 as Titan XT shipments are planned for 2H 2026 - MSN
3 Healthcare Stocks We Think Twice About - Yahoo Finance
A Look at Omnicell Inc (OMCL) After 3.6% Gain -- GF Value $38.63 vs Price $44.73 - GuruFocus
Omnicell Inc Stock (OMCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):